Eli Lilly and Company $LLY Position Increased by Madison Asset Management LLC

Madison Asset Management LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 60,914 shares of the company’s stock after buying an additional 2,058 shares during the period. Madison Asset Management LLC’s holdings in Eli Lilly and Company were worth $65,463,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after buying an additional 1,006,885 shares in the last quarter. State Street Corp lifted its stake in Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after buying an additional 219,590 shares in the last quarter. Capital Research Global Investors lifted its stake in Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares in the last quarter. Wellington Management Group LLP lifted its stake in Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after buying an additional 574,229 shares in the last quarter. Finally, Capital International Investors lifted its stake in Eli Lilly and Company by 6.1% during the third quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock valued at $7,628,447,000 after buying an additional 579,381 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s new phase 3 obesity data suggest Foundayo and lower-dose Zepbound can preserve weight-loss results, strengthening confidence in its obesity franchise and future growth. Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
• Positive Sentiment: Coverage highlighting Lilly’s strategy to expand beyond tirzepatide with next-generation obesity drugs, including an oral pill and retatrutide, may reassure investors that the company is protecting its leadership position. Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
• Positive Sentiment: Additional long-term data for Omvoh in ulcerative colitis adds another proof point for Lilly’s non-obesity pipeline and supports the broader growth story. Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal
• Neutral Sentiment: Lilly is celebrating its 150th anniversary with various company, community, and leadership-profile stories, but these are mostly reputational and unlikely to move the stock much on their own. Lilly CEO David Ricks keeps eye on future while company celebrates history
• Neutral Sentiment: Reuters reported Lilly launched its Alzheimer’s drug in India, a positive commercial development, but the immediate financial impact may be limited given the market’s focus on obesity growth. Eli Lilly launches Alzheimer’s drug Donanemab in India
• Negative Sentiment: Rival GLP-1 developers and new obesity entrants, including Kailera Therapeutics, add competitive pressure and show that Lilly’s market will remain highly contested. This Weight-Loss Drug Challenger Could Follow Eli Lilly’s Playbook: Analyst
• Negative Sentiment: Reports that Lilly paused an obesity awareness campaign in India after regulatory notices could be a modest headwind, though it does not appear to be a major earnings issue. Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report

Analyst Ratings Changes

LLY has been the subject of a number of analyst reports. Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Wolfe Research reiterated an “outperform” rating and issued a $1,325.00 target price on shares of Eli Lilly and Company in a report on Monday, May 4th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,218.33.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,014.93 on Thursday. The company has a market capitalization of $955.80 billion, a price-to-earnings ratio of 36.05, a P/E/G ratio of 1.08 and a beta of 0.48. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The business’s 50-day moving average is $939.87 and its 200-day moving average is $995.67.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.